• Recruiting

NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Updated: May 26

Multiple Myeloma Research Consortium

MMRC-089: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)


NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Anti-LAG-3 Monoclonal Antibody BMS-986016

This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles.


A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.


Sponsor

Multiple Myeloma Research Consortium


Collaborators

Bristol-Myers Squibb

Emory University

Washington University School of Medicine

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

Atrium Health

Memorial Sloan Kettering Cancer Center

Icahn School of Medicine at Mount Sinai

University of Texas

Hackensack Meridian Health

University of Michigan

 

ClinicalTrials.gov Identifier: NCT04136756


Official Title: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)


First Posted : November 5, 2019


Click here for details on ClinicalTrials.gov


Click here for details on cancer.gov

 

Anti-TIGIT monoclonal antibody BMS-986207

Anti-TIGIT: National Cancer Institute

View this agent in the NCI Thesaurus


Relatlimab

Anti-LAG-3 Monoclonal Antibody BMS-986016

Anti-LAG-3: National Cancer Institute

View this agent in the NCI Thesaurus


Drug: Elotuzumab, pomalidomide, dexamethasone

Drug: Anti-LAG-3

Drug: Anti-LAG-3 + Pomalidimide + Dexamethasone

Drug: Anti-TIGIT

Drug: Anti-TIGIT + Pomalidimide + Dexamethasone

 

Locations

United States, Georgia

United States, Massachusetts

United States, Michigan

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Texas

Posts Archive